These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 15753401

  • 1. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG.
    Cancer Res; 2005 Mar 01; 65(5):2009-17. PubMed ID: 15753401
    [Abstract] [Full Text] [Related]

  • 2. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
    Lozupone F, Rivoltini L, Luciani F, Venditti M, Lugini L, Cova A, Squarcina P, Parmiani G, Belardelli F, Fais S.
    Eur J Immunol; 2003 Feb 01; 33(2):556-66. PubMed ID: 12645955
    [Abstract] [Full Text] [Related]

  • 3. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J, Brück J, Lenz J, Knop J, Tüting T.
    Cancer Res; 2001 Dec 15; 61(24):8643-6. PubMed ID: 11751377
    [Abstract] [Full Text] [Related]

  • 4. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 15; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
    Mendiratta SK, Thai G, Eslahi NK, Thull NM, Matar M, Bronte V, Pericle F.
    Cancer Res; 2001 Feb 01; 61(3):859-63. PubMed ID: 11221870
    [Abstract] [Full Text] [Related]

  • 6. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA.
    Cancer Res; 2001 Aug 15; 61(16):6178-84. PubMed ID: 11507070
    [Abstract] [Full Text] [Related]

  • 7. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW, de Boer AJ, Figdor CG, Adema GJ.
    Cancer Res; 1998 Jun 15; 58(12):2509-14. PubMed ID: 9635569
    [Abstract] [Full Text] [Related]

  • 8. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M, Küpcü Z, Schüller S, Zalusky D, Zehetner M, Paster W, Schweighoffer T.
    Cancer Res; 2002 Oct 01; 62(19):5489-94. PubMed ID: 12359758
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM, Odesa SK, Liau LM.
    Cancer Res; 2003 Dec 01; 63(23):8487-91. PubMed ID: 14679014
    [Abstract] [Full Text] [Related]

  • 10. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
    Jorritsma A, Bins AD, Schumacher TN, Haanen JB.
    Cancer Res; 2008 Apr 01; 68(7):2455-62. PubMed ID: 18381454
    [Abstract] [Full Text] [Related]

  • 11. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma.
    O I, Blaszczyk-Thurin M, Shen CT, Ertl HC.
    Cancer Gene Ther; 2003 Sep 01; 10(9):678-88. PubMed ID: 12944987
    [Abstract] [Full Text] [Related]

  • 12. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity.
    Kim JH, Chen J, Majumder N, Lin H, Falo LD, You Z.
    Gene Ther; 2005 Oct 01; 12(20):1517-25. PubMed ID: 16052205
    [Abstract] [Full Text] [Related]

  • 13. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
    Pedersen SR, Sørensen MR, Buus S, Christensen JP, Thomsen AR.
    J Immunol; 2013 Oct 01; 191(7):3955-67. PubMed ID: 24018273
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
    Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tüting T.
    Cancer Res; 2006 May 15; 66(10):5427-35. PubMed ID: 16707471
    [Abstract] [Full Text] [Related]

  • 15. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W.
    J Gene Med; 2007 Aug 15; 9(8):715-26. PubMed ID: 17595048
    [Abstract] [Full Text] [Related]

  • 16. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Søgaard M, Andersson J, Andersson U.
    Br J Cancer; 1999 Sep 15; 81(2):359-66. PubMed ID: 10496366
    [Abstract] [Full Text] [Related]

  • 17. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F, Mao YQ, Kan B, He QM, Jiang Y, Peng F, Yang L, Tian L.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov 15; 35(6):757-60. PubMed ID: 15573746
    [Abstract] [Full Text] [Related]

  • 18. A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.
    Qu P, Ma JH, Zhang XM, Huang XJ, Yang XW, Yan-Fang S.
    Indian J Exp Biol; 2010 May 15; 48(5):436-43. PubMed ID: 20795360
    [Abstract] [Full Text] [Related]

  • 19. A simple method to cure established tumors by inflammatory killing of normal cells.
    Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG.
    Nat Biotechnol; 2004 Sep 15; 22(9):1125-32. PubMed ID: 15300260
    [Abstract] [Full Text] [Related]

  • 20. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
    Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E.
    Cancer Res; 2005 Dec 01; 65(23):11156-63. PubMed ID: 16322266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.